Coverage
-
September 06, 2017
Daiichi Sankyo Inc. on Wednesday asked a Pennsylvania federal judge if it could intercede in a rival's suit challenging the U.S. Food and Drug Administration's approval of abuse-deterrent opioid RoxyBond, saying it has a direct interest in the case's outcome.
2 other articles on this case.
View all »